Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease

American Journal of Pathology

Volumn 156, Issue 2, 2000, Pages 489-499

  Stoltzner, S E ^a   Grenfell, T J ^a   Mori, C ^a   Wisniewski, K E ^a   Wisniewski, T M ^a   Selkoe, D J ^a   Lemere, C A ^a  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CLUSTERIN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4D; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADOLESCENT; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; COMPLEMENT SYSTEM; DOWN SYNDROME; GLIOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROGLIA; NEURITE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SENILE PLAQUE;

EID: 0033888999     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64753-0     Document Type: Article

References (44)

1. Microtubule-associated protein, tau, is a major antigenic component of paired helical filaments in Alzheimer's disease
2. Microtubule-associated protein tau: A component of Alzheimer paired helical filaments
3. Tau mutations cause frontotemporal dementias
4. Translating cell biology into therapeutic advances in Alzheimer's disease
5. Amyloid A4 protein, and its precursor in Down's syndrome and Alzheimer's disease
6. Cerebral amyloidosis, aging and Alzheimer's disease: A contribution from studies on Down's syndrome
7. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome
8. Sequence of deposition of heterogeneous amyloid β-peptides and Apo E in Down syndrome: Implications for initial events in amyloid plaque formation
9. A prospective study of Alzheimer's disease in Down syndrome
10. The time course of pathological events in Down's syndrome with particular reference to the involvement of microglial cells and deposits of β/A4
11. Cerebral extracellular preamyloid deposits in Alzheimer's disease, Down syndrome and nondemented elderly individuals
12. Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study
13. Complement proteins and complement inhibitors in Alzheimer's disease
14. Complement activation and β-amyloid-mediated neurotoxicity in Alzheimer's disease
15. Localization and cell association of Clq in Alzheimer's disease brain
16. Complement Clq does not bind monomeric β-amyloid
17. Complement activation by β-amyloid in Alzheimer disease
18. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the Clq A chain
19. Multivalent binding of complement protein Clq to the amyloid β-peptide promotes the nucleation phase of Aβ aggregation
20. Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: Complement activation and therapeutic approaches
21. Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis
22. Charge-based binding of complement component Clq to the Alzheimer amyloid β-peptide
23. Complement activation by cross-linked truncated and chimeric full-length β-amyloid
24. Complement activation in amyloid plaques in Alzheimer's dementia
25. Activation of the classical complement pathway in brain tissue of Alzheimer patients
26. Up-regulated production and activation of the complement system in Alzheimer's disease brain
27. Immune system response in Alzheimer's disease
28. Association of amyloid P component with complement proteins in neurologically diseased brain tissue
29. Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain
30. The cerebrospinal-fluid soluble form of Alzheimer's amyloid β is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex
31. Complement-dependent pro-inflammatory properties of the Alzheimer's disease β-peptide
32. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease
33. Development of a highly sensitive capture EIA for the quantitation of the SC5b-9 complex in human plasma using a monoclonal antibody reactive with a poly-C9 neoantigenic determinant
34. Complement and cytokine gene expresson in cultured microglia derived from postmortem human brains
35. Neurons express proteins of the classical complement pathway in Alzheimer disease
36. β-Amyloid peptides initiate the complement cascade without producing a comparable effect on the terminal pathway in vitro
37. Sulfated glycoprotein 2: New relationships to this multifunctional protein to neurodegeneration
38. Purification and characterization of brain clusterin
39. Apolipoprotein J and Alzheimer's amyloid β solubility
40. Neuroimmune mechanisms in the pathogenesis of Alzheimer's disease
41. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain
42. Inhibition of respiratory burst in macrophages by complement receptor blockade
43. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases